162 related articles for article (PubMed ID: 12760868)
1. Antiviral activity and pharmacokinetics of 1-(2,3-dideoxy-2-fluoro-beta-L-glyceropent-2-enofuranosyl)cytosine.
Chen H; Pai SB; Hurwitz SJ; Chu CK; Glazkova Y; McClure HM; Feitelson M; Schinazi RF
Antimicrob Agents Chemother; 2003 Jun; 47(6):1922-8. PubMed ID: 12760868
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of the antiviral agent beta-L-3'-fluoro-2',3'-didehydro-2',3'-dideoxycytidine in rhesus monkeys.
Asif G; Hurwitz SJ; Gumina G; Chu CK; McClure HM; Schinazi RF
Antimicrob Agents Chemother; 2005 Feb; 49(2):560-4. PubMed ID: 15673733
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics, oral bioavailability, and metabolism in mice and cynomolgus monkeys of (2'R,5'S-)-cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl] cytosine, an agent active against human immunodeficiency virus and human hepatitis B virus.
Frick LW; Lambe CU; St John L; Taylor LC; Nelson DJ
Antimicrob Agents Chemother; 1994 Dec; 38(12):2722-9. PubMed ID: 7695253
[TBL] [Abstract][Full Text] [Related]
4. Comparative evaluation of L-Fd4C and related nucleoside analogs as promising antiviral agents.
Chen SH
Curr Med Chem; 2002 May; 9(9):899-912. PubMed ID: 11966452
[TBL] [Abstract][Full Text] [Related]
5. Antiviral activity of beta-L-2',3'-dideoxy-2',3'-didehydro-5-fluorocytidine in woodchucks chronically infected with woodchuck hepatitis virus.
Le Guerhier F; Pichoud C; Jamard C; Guerret S; Chevallier M; Peyrol S; Hantz O; King I; Trépo C; Cheng YC; Zoulim F
Antimicrob Agents Chemother; 2001 Apr; 45(4):1065-77. PubMed ID: 11257017
[TBL] [Abstract][Full Text] [Related]
6. Anti-hepatitis B virus activity and metabolism of 2',3'-dideoxy-2',3'-didehydro-beta-L(-)-5-fluorocytidine.
Zhu YL; Dutschman DE; Liu SH; Bridges EG; Cheng YC
Antimicrob Agents Chemother; 1998 Jul; 42(7):1805-10. PubMed ID: 9661025
[TBL] [Abstract][Full Text] [Related]
7. Characterization of hepatitis B virus inhibition by novel 2'-fluoro-2',3'-unsaturated beta-D- and L-nucleosides.
Pai SB; Pai RB; Xie MY; Beker T; Shi J; Tharnish PM; Chu CK; Schinazi RF
Antivir Chem Chemother; 2005; 16(3):183-92. PubMed ID: 16004081
[TBL] [Abstract][Full Text] [Related]
8. Use of the hepatitis B virus recombinant baculovirus-HepG2 system to study the effects of (-)-beta-2',3'-dideoxy-3'-thiacytidine on replication of hepatitis B virus and accumulation of covalently closed circular DNA.
Delaney WE; Miller TG; Isom HC
Antimicrob Agents Chemother; 1999 Aug; 43(8):2017-26. PubMed ID: 10428929
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and biological evaluation of 2',3'-dideoxy-L-pyrimidine nucleosides as potential antiviral agents against human immunodeficiency virus (HIV) and hepatitis B virus (HBV).
Lin TS; Luo MZ; Liu MC; Pai SB; Dutschman GE; Cheng YC
J Med Chem; 1994 Mar; 37(6):798-803. PubMed ID: 8145230
[TBL] [Abstract][Full Text] [Related]
10. Characterization of the antiviral effect of 2',3'-dideoxy-2', 3'-didehydro-beta-L-5-fluorocytidine in the duck hepatitis B virus infection model.
Le Guerhier F; Pichoud C; Guerret S; Chevallier M; Jamard C; Hantz O; Li XY; Chen SH; King I; Trépo C; Cheng YC; Zoulim F
Antimicrob Agents Chemother; 2000 Jan; 44(1):111-22. PubMed ID: 10602731
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of the antiviral agent beta-D-2',3'-didehydro-2',3'-dideoxy-5-fluorocytidine in rhesus monkeys.
Ma L; Hurwitz SJ; Shi J; Mcatee JJ; Liotta DC; McClure HM; Schinazi RF
Antimicrob Agents Chemother; 1999 Feb; 43(2):381-4. PubMed ID: 9925539
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics, oral bioavailability, and metabolic disposition in rats of (-)-cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl] cytosine, a nucleoside analog active against human immunodeficiency virus and hepatitis B virus.
Frick LW; St John L; Taylor LC; Painter GR; Furman PA; Liotta DC; Furfine ES; Nelson DJ
Antimicrob Agents Chemother; 1993 Nov; 37(11):2285-92. PubMed ID: 8285607
[TBL] [Abstract][Full Text] [Related]
13. Antiviral activity and intracellular metabolism of bis(tButylSATE) phosphotriester of beta-L-2',3'dideoxyadenosine, a potent inhibitor of HIV and HBV replication.
Placidi L; Faraj A; Loi AG; Pierra C; Egron D; Cretton-Scott E; Gosseli G; Périgaud C; Martin LT; Schinazi RF; Imbach JL; el Kouni MH; Bryant ML; Sommadossi JP
Antivir Chem Chemother; 2001 Mar; 12(2):99-108. PubMed ID: 11527047
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and metabolism of racemic 2',3'-dideoxy-5-fluoro-3'-thiacytidine in rhesus monkeys.
Schinazi RF; Boudinot FD; Ibrahim SS; Manning C; McClure HM; Liotta DC
Antimicrob Agents Chemother; 1992 Nov; 36(11):2432-8. PubMed ID: 1336946
[TBL] [Abstract][Full Text] [Related]
15. Clinical pharmacokinetics of the antiviral nucleotide analogues cidofovir and adefovir.
Cundy KC
Clin Pharmacokinet; 1999 Feb; 36(2):127-43. PubMed ID: 10092959
[TBL] [Abstract][Full Text] [Related]
16. Preclinical Characterization of NVR 3-778, a First-in-Class Capsid Assembly Modulator against Hepatitis B Virus.
Lam AM; Espiritu C; Vogel R; Ren S; Lau V; Kelly M; Kuduk SD; Hartman GD; Flores OA; Klumpp K
Antimicrob Agents Chemother; 2019 Jan; 63(1):. PubMed ID: 30373799
[TBL] [Abstract][Full Text] [Related]
17. Sensitivity of L-(-)2,3-dideoxythiacytidine resistant hepatitis B virus to other antiviral nucleoside analogues.
Fu L; Liu SH; Cheng YC
Biochem Pharmacol; 1999 Jun; 57(12):1351-9. PubMed ID: 10353255
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of the anti-human immunodeficiency virus agent 1-(beta-D-dioxolane)thymine in rhesus monkeys.
Asif G; Hurwitz SJ; Obikhod A; Delinsky D; Narayanasamy J; Chu CK; McClure HM; Schinazi RF
Antimicrob Agents Chemother; 2007 Jul; 51(7):2424-9. PubMed ID: 17485498
[TBL] [Abstract][Full Text] [Related]
19. N-terminal and C-terminal cytosine deaminase domain of APOBEC3G inhibit hepatitis B virus replication.
Lei YC; Tian YJ; Ding HH; Wang BJ; Yang Y; Hao YH; Zhao XP; Lu MJ; Gong FL; Yang DL
World J Gastroenterol; 2006 Dec; 12(46):7488-96. PubMed ID: 17167839
[TBL] [Abstract][Full Text] [Related]
20. Perspectives for the treatment of hepatitis B virus infections.
De Clercq E
Int J Antimicrob Agents; 1999 Jul; 12(2):81-95. PubMed ID: 10418752
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
